These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 803302)

  • 1. Different effector cell types in antibody-dependent cell-mediated cytotoxicity.
    Sanderson CJ; Clark IA; Taylor GA
    Nature; 1975 Jan; 253(5490):376-7. PubMed ID: 803302
    [No Abstract]   [Full Text] [Related]  

  • 2. The relative distribution of cytotoxic lymphocytes and of alloantibody-forming cells in albumin density gradients.
    Pelet J; Brunner KT; Nordin AA; Cerottini JC
    Eur J Immunol; 1971 Aug; 1(4):238-42. PubMed ID: 5003410
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody-dependent cell-mediated cytotoxicity. III. Two functionally different effector cells.
    Scornik JC; Cosenza H
    J Immunol; 1974 Nov; 113(5):1527-32. PubMed ID: 4213695
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody-dependent cell-mediated cytotoxicity. II. Early interactions between effector and target cells.
    Scornik JC
    J Immunol; 1974 Nov; 113(5):1519-26. PubMed ID: 4418199
    [No Abstract]   [Full Text] [Related]  

  • 5. Cooperation and cell-mediated cytotoxicity as functions of two subsets of T cells.
    Dennert G; Lennox ES
    J Immunol; 1974 Nov; 113(5):1553-61. PubMed ID: 4213868
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: Cytotoxicity after B.C.G. infection.
    Koszinowski U; Volkmann B
    Lancet; 1974 Mar; 1(7856):508. PubMed ID: 4131909
    [No Abstract]   [Full Text] [Related]  

  • 7. Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. I. Phagocytic and non-phagocytic effector cell activity against erythrocyte and tumour target cells in a 51Cr release cytotoxicity assay and [125I]IUdR growth inhibition assay.
    Greenberg AH; Shen L; Medley G
    Immunology; 1975 Oct; 29(4):719-29. PubMed ID: 810417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte-mediated cytotoxicity against tumor cells. I. Con A activated cytotoxic effector cells exhibit immunological specificity.
    Waterfield JD; Waterfield EM; Möller G
    Cell Immunol; 1975 Jun; 17(2):392-404. PubMed ID: 805001
    [No Abstract]   [Full Text] [Related]  

  • 9. Phagocytic cells as effectors in a cell-mediated immunity system.
    Dennert G; Lennox ES
    J Immunol; 1973 Dec; 111(6):1844-54. PubMed ID: 4543031
    [No Abstract]   [Full Text] [Related]  

  • 10. The mechanism of K cell (antibody-dependent) cell mediated cytotoxicity. II. Characteristics of the effector cell and morphological changes in the target cell.
    Sanderson CJ; Thomas JA
    Proc R Soc Lond B Biol Sci; 1977 Jul; 197(1129):417-24. PubMed ID: 18739
    [No Abstract]   [Full Text] [Related]  

  • 11. Age-related changes in antibody-dependent cell-mediated cytotoxicity in mouse spleen.
    Becker MJ; Roubinian J; Feldmann JL; Blackman MA; Klajman A; Talal N
    Isr J Med Sci; 1979 Feb; 15(2):147-50. PubMed ID: 468522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effector mechanisms of cell-mediated immunity to xenogeneic cell antigens.
    Dennert G
    J Immunol; 1974 Jul; 113(1):201-8. PubMed ID: 4208918
    [No Abstract]   [Full Text] [Related]  

  • 13. Separation of effector cells mediating antibody-dependent cellular cytotoxicity (ADC) to erythrocyte targets from those mediating ADC to tumor targets.
    Pollack SB; Nelson K; Grausz JD
    J Immunol; 1976 Apr; 116(4):944-6. PubMed ID: 815438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional capacity of cytotoxic lymphoid cells.
    Wunderlich JR; Martin WJ; Macdonald J; Fletcher F
    Natl Cancer Inst Monogr; 1972 Dec; 35():243-9. PubMed ID: 4676543
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody-dependent cell-mediated cytotoxicity. Comparative ability of murine Peyer's patch and spleen cells to lyse lipopolysaccharide-coated and uncoated erythrocytes.
    Kagnoff MF; Campbell S
    Gastroenterology; 1976 Mar; 70(3):341-6. PubMed ID: 1082425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of enhancing antibody in cell mediated immunity to tumour heterografts in protein deficient rats.
    Jose DG; Good RA
    Nature; 1971 Jun; 231(5301):323-5. PubMed ID: 4996061
    [No Abstract]   [Full Text] [Related]  

  • 17. Fractionation of immunocompetent spleen cells by albumin density gradient centrifugation.
    Möller G; Hiesche K
    Immunology; 1970 Apr; 18(4):585-94. PubMed ID: 4393021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between proliferative and effector phases of the mixed lymphocyte reaction and graft-vs-host reaction.
    Howe M; Berman L; Cohen L
    J Immunol; 1973 Oct; 111(4):1243-9. PubMed ID: 4147022
    [No Abstract]   [Full Text] [Related]  

  • 19. Separation of stages in the development of the "T" cells involved in cell-mediated immunity.
    Shortman K; Brunner KT; Cerottini JC
    J Exp Med; 1972 Jun; 135(6):1375-91. PubMed ID: 4623609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of K cell (antibody-dependent) cell mediated cytotoxicity. I. The release of different cell components.
    Sanderson CJ; Thomas JA
    Proc R Soc Lond B Biol Sci; 1977 Jul; 197(1129):407-15. PubMed ID: 18738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.